Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers
- PMID: 25488685
- DOI: 10.1093/annonc/mdu565
Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers
Erratum in
-
Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers.Ann Oncol. 2016 Jun;27(6):1181. doi: 10.1093/annonc/mdw096. Epub 2016 Mar 3. Ann Oncol. 2016. PMID: 26945009 No abstract available.
Abstract
Background: Polygenic risk profiles computed from multiple common susceptibility alleles for breast cancer have been shown to identify women at different levels of breast cancer risk. We evaluated whether this genetic risk stratification can also be applied to discriminate between screen-detected and interval cancers, which are usually associated with clinicopathological and survival differences.
Patients and methods: A 77 single-nucleotide polymorphism polygenic risk score (PRS) was constructed for breast cancer overall and by estrogen receptor (ER) status. PRS was inspected as a continuous (per standard deviation increment) variable in a case-only design. Modification of the PRS by mammographic density was evaluated by fitting an additional interaction term.
Results: PRS weighted by breast cancer overall estimates was found to be differentially associated with 1865 screen-detected and 782 interval cancers in the LIBRO-1 study {age-adjusted odds ratio (OR)perSD [95% confidence interval (CI)] 0.91 [0.83-0.99], P = 0.023}. The association was found to be more significant for PRS weighted by ER-positive breast cancer estimates [ORperSD = 0.90 (0.82-0.98), P = 0.011]. This result was corroborated by two independent studies [combined ORperSD = 0.87 (0.76-1.00), P = 0.058] with no evidence of heterogeneity. When enriched for 'true' interval cancers among nondense breasts, the difference in the association with PRS in screen-detected and interval cancers became more pronounced [ORperSD = 0.74 (0.62-0.89), P = 0.001], with a significant interaction effect between PRS and mammographic density (Pinteraction = 0.017).
Conclusion: To our knowledge, this is the first report looking into the genetic differences between screen-detected and interval cancers. It is an affirmation that the two types of breast cancer may have unique underlying biology.
Keywords: personalized medicine; polygenic risk score.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Risk factors and tumor characteristics of interval cancers by mammographic density.J Clin Oncol. 2015 Mar 20;33(9):1030-7. doi: 10.1200/JCO.2014.58.9986. Epub 2015 Feb 2. J Clin Oncol. 2015. PMID: 25646195
-
Mammographic density and survival in interval breast cancers.Breast Cancer Res. 2013 Jun 20;15(3):R48. doi: 10.1186/bcr3440. Breast Cancer Res. 2013. PMID: 23786804 Free PMC article.
-
Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants.Breast Cancer Res Treat. 2019 Jul;176(1):141-148. doi: 10.1007/s10549-019-05210-2. Epub 2019 Apr 2. Breast Cancer Res Treat. 2019. PMID: 30941651 Free PMC article.
-
Using tumor phenotype, histological tumor distribution, and mammographic appearance to explain the survival differences between screen-detected and clinically detected breast cancers.APMIS. 2014 Aug;122(8):699-707. doi: 10.1111/apm.12294. APMIS. 2014. PMID: 25046200 Review.
-
[Interest in the use of polygenic risk scores in breast cancer screening and preventive medicine].Rev Med Liege. 2024 Jun;79(5-6):372-378. Rev Med Liege. 2024. PMID: 38869126 Review. French.
Cited by
-
Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women.J Clin Oncol. 2024 May 1;42(13):1477-1487. doi: 10.1200/JCO.23.00295. Epub 2024 Feb 29. J Clin Oncol. 2024. PMID: 38422475 Free PMC article.
-
Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns.Int J Cancer. 2021 Feb 15;148(4):884-894. doi: 10.1002/ijc.33270. Epub 2020 Sep 5. Int J Cancer. 2021. PMID: 32856720 Free PMC article.
-
Fatty acid synthetase expression in triple-negative breast cancer.J Pathol Transl Med. 2022 Mar;56(2):73-80. doi: 10.4132/jptm.2021.10.27. Epub 2022 Jan 21. J Pathol Transl Med. 2022. PMID: 35051326 Free PMC article.
-
Incidence and Risk Factors of Interval and Screen-Detected Breast Cancer.JAMA Oncol. 2025 May 1;11(5):519-527. doi: 10.1001/jamaoncol.2025.0167. JAMA Oncol. 2025. PMID: 40146116
-
Progress in Polygenic Composite Scores in Alzheimer's and Other Complex Diseases.Trends Genet. 2019 May;35(5):371-382. doi: 10.1016/j.tig.2019.02.005. Epub 2019 Mar 25. Trends Genet. 2019. PMID: 30922659 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical